Tech Company Financing Transactions
ARTBIO Funding Round
ARTBIO, operating out of Cambridge, secured $90 million from Third Rock Ventures, F-Prime Capital and Omega Funds.
Transaction Overview
Company Name
Announced On
12/7/2023
Transaction Type
Venture Equity
Amount
$90,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to solidify its proprietary Pb212 isolation technology AlphaDirect� and its distributed manufacturing network, advance its lead program AB001 in the clinic for treatment of prostate cancer, and further the pipeline.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Cambridge, MA Undisclosed
USA
Cambridge, MA Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Overview
ARTBIO is redefining cancer care by developing a new class of alpha radioligand therapies (ART) and building the ecosystem that maximizes their potential.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Emanuele Ostuni
Chief Technical Officer
Philippe Dasse
Browse more venture capital transactions:
Prev: 12/7/2023: Milliman venture capital transaction
Next: 12/7/2023: InpharmD venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. VC investment data records reported here come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs